Protalix BioTherapeutics Reports Positive Long Term Data on PRX-102 for Fabry Disease

By: via Benzinga
Protalix BioTherapeutics, Inc. (NYSE MKT: PLX) (TASE:PLX), announced today positive long term data from the 0.2mg, or lowest dose, of ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.